U.S. VASOPRESSIN MARKET ANALYSIS

Vasopressin is antidiuretic hormone. It is naturally secreted by the pituitary gland, which acts on the kidneys and blood vessels. Vasopressin can be used to treat diabetes insipidus through different routes of administration such as intravenous injection, intramuscular injection, and others.

Vasopressin is widely available in the U.S. and is expected to fuel the growth of U.S. vasopressin market over the forecast period. Some examples of vasopressin injections available in the U.S. for treatment of diabetes include vasopressin injection (Eagle Pharmaceuticals, Inc.), pitressin injection (JHP Pharmaceuticals, LLC), and others.

U.S. Vasopressin Market - Impact of the Coronavirus (COVID-19) Pandemic

The supply chain of vasopressin has been hampered to a certain extend in the U.S., owing to global lockdowns and transportation limitations during the COVID-19 pandemic. The COVID-19 pandemic has impacted the U.S. economy and in turn, the U.S. vasopressin market. Quarantines, traveling constraints, and social distancing measures are likely to lead to a steep decline in the business and consumer spending.

However, key companies operating in the market are focusing on initiatives to enhance availability vasopressin for treatment of various diseases during COVID-9 pandemic which is expected to drive market growth over the forecast period.

For instance, in April 2020, Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company, announced an initiative to increase availability of Vaprisol (conivaptan hydrochloride) injection for treating hyponatremia, associated with critical care patients during the COVID-19 pandemic. Moreover, Vaprisol is an U.S. FDA approved treatment for hyponatremia, a potentially life-threatening condition that can often afflict patients in the Intensive Care Unit.

The U.S. vasopressin market is estimated to be valued at US$ 894.6 Mn in 2021, and is expected to exhibit a CAGR of 14.7% over the forecast period (2021-2028).

Figure 1: U.S. Vasopressin Market Share (%) Analysis, By Type, 2021

To learn more about this report, request sample copy

Increasing regulatory approvals of vasopressin is the major factor that is expected to drive growth of the U.S. vasopressin market over the forecast period.

Increasing regulatory approvals of vasopressin in the U.S. is expected to be the major factor driving the growth of U.S. vasopressin market over the forecast period. For instance, in December 2021, Eagle Pharmaceuticals, Inc., a U.S.-based pharmaceutical company, announced that the U.S. Food and Drug Administration approved the company’s abbreviated new drug application ‘ANDA’ for vasopressin.

High prevalence of chronic diseases and health conditions such as diabetes insipidus, cardiovascular diseases, septic shock, and others is expected to augment the market growth

High prevalence of chronic diseases and health conditions such as diabetes insipidus, cardiovascular diseases, septic shock, and others in the U.S. is expected to be the major factor driving the growth of U.S. vasopressin market over the forecast period, as vasopressin can be used for the treatment of aforementioned health conditions and ailments. For instance, according to an article published by the JAMA Network Open journal in February 2019, on the basis of data collected from January 1, 2017 to March 31, 2018, it is estimated that 52.8% of hospitalized patients in the U.S. had sepsis and it was found to be the immediate cause of death in 34.9% of the hospitalized patients. The same source also estimates that around 1.7 million adults in the U.S. are affected from sepsis each year, which contributes to more than 250,000 deaths each year.

Figure 2: U.S. Vasopressin Market Share (%) Analysis, By Application, 2021

To learn more about this report, request sample copy

U.S. Vasopressin Market – Restraints

Complications related to the use of vasopressin such as cardiac arrest, asthma, and others is expected to act as a restraint for the U.S. vasopressin market over the forecast period. For instance, according to an article published by the Journal of International Medical Research in October 2018, if high concentration of vasopressin is administered into a patient, the vasopressin in the blood can induce adverse events such as gastrointestinal ischemia bradycardia, myocardial ischemia, and others. In some severe cases, the high concentration of vasopressin may also lead to myocardial infarction or cardiac arrest.

U.S. Vasopressin Market – Competitive Landscape

Major players operating in the U.S. vasopressin market include Par Pharmaceutical, Pfizer Inc., Eagle Pharmaceuticals, Inc., Astellas Pharma Inc., Cumberland Pharmaceuticals Inc., Dr. Reddy’s Laboratories Ltd., Athenex, Inc., Otsuka Holdings Co., Ltd, and Azevan Pharmaceuticals, Inc.